Citius Oncology, Inc. (CTOR)
| Market Cap | 111.05M -26.5% |
| Revenue (ttm) | 7.11M |
| Net Income | -46.06M |
| EPS | -0.49 |
| Shares Out | 105.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26,667 |
| Open | 1.070 |
| Previous Close | 1.050 |
| Day's Range | 1.020 - 1.070 |
| 52-Week Range | 0.491 - 2.250 |
| Beta | 3.53 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About CTOR
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.
Full Company ProfileFinancial Performance
Financial StatementsNews
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference and Moody Capital Solutions 2026 Disruptive Growth & Lif...
Citius Oncology Proxy statement: Proxy filing
Citius Oncology filed a proxy statement on August 26, 2026, providing details for shareholder voting and corporate governance matters.
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ® $17 million in cash and cash equivalents as of June 30, 2026 Expanded LYMPHIR commercial and medical...
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
$7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR ® launch progresses Strong institutional demand drives growth in total vials ordered and number of institutions ordering...
Citius Oncology Quarterly report: Q3 2026
Citius Oncology has published its Q3 2026 quarterly earnings report on August 14, 2026.
Citius Oncology Earnings release: Q3 2026
Citius Oncology released its Q3 2026 earnings on August 14, 2026, summarizing the period's financial results.
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
CRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceut...
Citius Oncology reports availability of Lymphir in institutions grew 78% in Q3
Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, (CTXR), provided an update on the expanding base of institutions ordering LYMPHIR, or denileukin diftitox-cxdl through wh...
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
New institutional accounts ordering LYMPHIR increased 78% quarter over quarter LYMPHIR's near-universal payer coverage expands market access Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR...
Citius Oncology provides update on commercial launch of Lymphir
Citius Oncology (CTOR), majority-owned subsidiary of Citius Pharmaceuticals (CTXR), provided an update on the commercial launch of Lymphir – denileukin diftitox-cxdl -. Citius Oncology has expanded it...
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. by August CRANFORD, N.J., July 21, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Na...
Citius Oncology highlights Phase 1 data evaluating Lymphir at ASCO
Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals (CTXR), highlighted Phase 1 clinical data presented May 30 at the American Society of Clinical Oncology Annual Meeting eva...
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated durable responses and manageable tolerability in heavily pre-t...
Citius Oncology registers to sell 32.93M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholder of up to 32.93M shares of common stock. The company is not selling any…
Citius Oncology Registration statement: Registration filing
Citius Oncology filed a registration statement on May 29, 2026, providing details about a securities offering with the SEC.
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
24% Objective Response Rate, with an average of 21.1 month Duration of Response in responders, and favorable safety profile signals potential of LYMPHIR to augment immune checkpoint inhibitor efficacy...
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
$5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR ® Citius Pharma raised $5 million in a registered direct offering; Citius Oncology secured up to $36.5 mill...
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
$5.6 million in net revenue for the first half of fiscal 2026 as LYMPHIR ® launch progresses Up to $36.5 million in debt and equity capital secured Broad payer coverage established with no reimburseme...
Citius Oncology Quarterly report: Q2 2026
Citius Oncology has published its Q2 2026 quarterly earnings report on May 15, 2026.
Citius Oncology Earnings release: Q2 2026
Citius Oncology released its Q2 2026 earnings on May 15, 2026, summarizing the period's financial results.
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization
Avenue Capital Group to provide up to $25 Million via Senior Credit Facility with an initial $10 million tranche funded at closing; additional tranches subject to certain conditions Gross proceeds of ...
Citius Oncology announces initial shipment of LYMPHIR to Europe
Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, (CTXR), announced the initial shipment of LYMPHIR to Europe through one of its regional distribution partners, marking an...
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch Distribution by regional partners through Named Patient Programs in specific international markets CRANFO...
Citius Oncology provides commercial update on lymphir launch
Citius Oncology (CTOR)provided a commercial update on the U.S. launch of lymphir for the treatment of cutaneous T-cell lymphoma, highlighting continued adoption across leading oncology centers, broad ...
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
Broad institutional uptake among leading cancer centers and payer coverage supports early prescribing momentum and clinical integration CRANFORD, N.J., March 31, 2026 /PRNewswire/ -- Citius Oncology, ...